A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO VERSUS PLACEBO IN COMBINATION WITH PHESGO AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA MUTATED HER2 POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

14475WO44263-INAVO122OpenA PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB IN COMBINATION WITH PHESGO VERSUS PLACEBO IN COMBINATION WITH PHESGO AS MAINTENANCE THERAPY AFTER FIRST LINE INDUCTION THERAPY IN PARTICIPANTS WITH PIK3CA MUTATED HER2 POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCERWO44263 (INAVO 122)NCT05894239Industrial; InstitutionalAdultTreatmentIIIGlobalOtherChitalia, AmiGeorgetown University Medical Center : Julie Castle, Antonella Novielli; Lombardi Comprehensive Cancer Center : Julie Castle, Antonella Novielli; MedStar Health and GUMC; Medstar Washington Hospital Center : Stacy MalloyBreastOncology GroupLombardi Comprehensive Cancer Center (LCCC); MHRI Washington Cancer Institute7263Julie CastleJulie Castle+1 202-687-2209bickmorj@georgetown.eduClinical Research Nurse 7311Antonella NovielliAntonella Novielli+1 202-784-3923+1 202-687-3372noviella@georgetown.eduClinical Research Nurse 10787Stacy MalloyStacy MalloyStacy.K.Malloy@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>